Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2008

View Archived Issues

Beta-cell function improved with R-1583, a novel long-acting GLP-1 analogue

Mechanism of action discovered for CGS-26303 in reduction of cerebral vasospasm

Limerick NeuroSciences changes name to Limerick BioPharma

Plethora completes European phase III trial of PSD-502 for premature ejaculation

New anticancer agents imparted in recent patents

Novel agents for rheumatoid arthritis disclosed in recent Janssen and Kyorin patents

Recent Rice University patent describes new antiinflammatory agents

Shire Limited changes name to Shire plc

FDA approves Reyataz boosted with ritonavir in HIV

Transcept submits NDA for Intermezzo for middle-of-the-night awakenings

Bioheart engages 35 U.S. heart failure centers in phase II/III MARVEL trial of MyoCell

Eurand revises guidance for anticipated approval and commercial launch of Zentase

GW Pharmaceuticals completes enrollment into phase III trial of Sativex in MS spasticity

Micromet signs definitive agreement for USD 40 million private equity placement

ALS submits NDA to FDA for cethromycin in CAP and signs agreement with Wyeth

Bayer Schering and the NUS enter agreement for preclinical cancer research

Pharmaxis submits MAA in Australia for Bronchitol in bronchiectasis

Ambrilia reports positive results for second phase III octreotide C2L study

Commercialization of Gatiflo discontinued in Japan

Merck & Co. discontinues taranabant development for obesity

Orexigen starts phase IIa OREX-003 trial in antipsychotic-associated weight gain

Pharmaleads advances its lead pain compound, PL-37, into phase I trials

Phase II/III study results reported for Arocyte for injection in Japan

Positive phase II results presented for rabies monoclonal antibody combination

R&D highlights from the UBS Global Life Sciences Conference in New York: Pharmasset

Merck & Co. identifies a novel bradykinin B1 antagonist

Motesanib plus standard chemotherapy safe and effective in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...